Yonesaka, Kimio
Kindai University
4 papers on CoChatORCID 0000-0002-0816-5315
Most cited papers
- Verified
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., et al. (2018) · JAMA Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 1,003
- Verified
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine
HER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies
Cited by 663
- Verified
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization
Cho, J., Chen, L., Sangji, N., Okabe, T., Yonesaka, K., Francis, J. M., Flavin, R. J., Johnson, W., Kwon, J., Yu, S., et al. (2013) · Cancer Research
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 117
- Verified
KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
Suzuki, S., Yonesaka, K., Teramura, T., Takehara, T., Kato, R., Sakai, H., Haratani, K., Tanizaki, J., Kawakami, H., Hayashi, H., et al. (2021) · Clinical Cancer Research
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 105
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free